Compare Regeneron Pharmaceuticals Inc (REGN) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs US Bancorp — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while US Bancorp trades at $56.58 (market cap $88.86B). The key difference: US Bancorp is the larger of the two by market cap, and US Bancorp pays the higher dividend (3.79%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and US Bancorp for 97 Days on average.
| REGN | USB | |
|---|---|---|
Market Cap | $76.14B | $88.86B |
Volume | 500,239 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $852.03 | $65.42 |
52-Week Low | $557.73 | $45.28 |
Typical Hold Time | 107 Days | 97 Days |
Enterprise Value | $70.85B | $118.35B |
Dividend Yield | 0.51% | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
U.S. Bancorp (USB) trades at $56.17, down 1.95% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock offers a $2.16 annual dividend yield with recent 3.8% increase. Analyst consensus is bullish with $69.94 price target despite near-term technical weakness.
USB presents a value opportunity with attractive P/E of 11.38 and strong profitability metrics, though investors face interest rate sensitivity and regulatory uncertainty risks. The bank's solid earnings track record and dividend growth support long-term investment case despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
